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The epidermal growth factor
receptor (EGFR) is a long known,
versatile signal transducer that has
been well conserved during
evolution. It functions in a wide
range of cellular processes including
cell fate determination, proliferation,
cell migration and apoptosis. The
activity of the EGFR is subject to
modulation by multiple positive and
negative regulators and is transduced
to the nucleus by several conserved
signaling cassettes. Here we will
briefly review the hallmarks of
EGFRs and their functions as well as
summarize some of the mechanisms
cells use to modulate EGFR activity.
EGFR structure
The EGFR belongs to the large
family of cell surface receptors with
intrinsic protein tyrosine kinase
(RTK) activity. At the plasma
membrane the unstimulated EGFR
is present as a monomer. Upon
binding of extracellular ligand, the
EGFR undergoes dimerization
resulting in trans-
autophosphorylation of its
cytoplasmic domain.
In vertebrates, four EGFR family
members are known: ErbB1, also
termed EGFR or HER1; ErbB2, also
termed Neu or HER2; ErbB3, or
HER3; and ErbB4, or HER4. The
overall amino acid identity between
these proteins is about 50%.
Caenorhabditis elegans and Drosophila
melanogaster contain only one gene
each encoding EGFR orthologues,
called Let-23 and DER respectively.
The different members of the EGFR
family share conserved structural
features that distinguish them from
other RTKs. All are type Ia
transmembrane proteins consisting
of an extracellular ligand-binding
domain, a single membrane-spanning
domain and a cytoplasmic protein
tyrosine kinase domain (Figure 1). 
The most outstanding feature of
the glycosylated extracellular domain
of these receptors is the presence of
conserved cysteine-rich clusters,
which comprise the ligand-binding
domain. All ErbB proteins contain
two cysteine-rich domains, CRI and
CRII, whereas their invertebrate
counterparts, Let-23 and DER, have
an additional cysteine-rich motif.
Within the cytoplasmic region
three conserved sequence domains
can be recognized. The
juxtamembrane region is required for
feedback attenuation by protein
kinase C (PKC). It is followed by the
tyrosine kinase domain — a Src
homology domain 1, SH1 (Figure 1).
This is the most conserved region
among the EGFR protein family —
except in ErbB3 — and it mediates
auto-phosphorylation of the carboxy-
terminal tail on six tyrosine residues.
The degree of evolutionary
conservation is significantly reduced
in the carboxy-terminal tail following
the kinase domain. Nevertheless, the
very carboxy-terminal tails of all
EGFR molecules have important
regulatory functions. The six
tyrosine autophosphorylation sites
are all located in the non-catalytic tail
of the receptors. Phosphorylated
tyrosine residues of the EGFR
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Figure 1
EGFR structure. The EGFR is a monomer
consisting of 1186 amino acids. Its
extracellular domain is characterized by two
cysteine-rich motifs (CR I and CRII). DER
and Let-23 have an additional CRIII domain.
The overall amino acid identity between the
human ErbB1 and Let-23 proteins is 29%
and that between DER and ErbB1 is 38%.
Amino acids in EGFR that can be
phosphorylated are indicated. TM,
transmembrane domain; JM, juxtamembrane
region.
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recruit various adapter proteins with
SH2 — Src homology domain 2 — or
PTB — phosphotyrosine binding —
domains to the membrane (Figure 2).
EGFR is also able to phosphorylate
target proteins such as phospholipase
Cγ, which binds directly to the
EGFR via its SH2 domain. In
addition, the EGFR can be
phosphorylated by other kinases
such as PKC, which regulates EGFR
distribution in the membrane.
Finally, the carboxy-terminal tail
contains motifs for internalization
and degradation of the receptor.
Following ligand binding, EGFR
dimers are recruited into clathrin-
coated pits. This initiates rapid
endocytosis which attenuates the
signal generated at the membrane.
Since the internalized receptor
remains active until it is sequestered
into late endosomes and targeted for
degradation, intracellular EGFR
signaling may be of biological
relevance.
Finally, it has been noted that
receptor downregulation can also be
affected by sorting in the early
endosomal compartment. For
example it appears that in contrast to
EGF, transforming growth factor-α
(TGF-α) bound to the EGFR can
already dissociate from the receptor
in the early endosomal compartment
leading to EGFR recycling as
compared to the lysosomal
degradation of EGF-bound
receptors. 
EGFR function
The ubiquitously expressed EGFR
is a pleiotropic signal transducer and
fulfills multiple roles during cell fate
determination, differentiation,
proliferation and apoptosis. The
ErbB1 protein is a prototype of the
EGFR family and its identification
provided one of the first links
between an activated oncogene and
the development of cancer. ErbB1 is
homologous to the product of the
viral oncogene v-erbB, which encodes
a truncated EGF receptor lacking
the extracellular EGF-binding
domain. In a large number of tumors
the expression status of ErbB1 is also
altered, due to overexpression or
mutation. Because of its oncogenic
potential, ErbB1 has been used as a
prognostic marker for many years.
The first evidence of the crucial
role of EGFR in cell differentiation
during vertebrate development
stems from EGF injection
experiments 24 years ago. Injected
mice showed precocious eye opening
and tooth eruption. The
fundamental role of EGFR in
development has since been
supported by numerous genetic
studies. Null mutations in the
individual ErbB loci are all
embryonic lethal at day
10.5–13.5 p.c. and induce
overlapping but not identical defects
in multiple organs including brain,
skin, lung, heart and eye.
C. elegans and Drosophila have
served as useful model systems for
studying the signaling processes
triggered by the EGF receptor. As
reflected by the many designations
given to mutant alleles — faint little
ball, torpedo and Ellipse — the
Drosophila EGFR homologue, DER,
is required at multiple times during
fly development. Its requirement
during axis determination and cell
fate decisions during embryonic and
imaginal disc development as well as
during oogenesis formed the basis for
several genetic studies that led to the
identification of conserved signaling
cassettes. In addition, genetic
analyses have unraveled numerous
regulatory mechanisms for EGFR
activity and provided new insights
into fundamental principles of
animal development and cancer.
Downstream of EGFR
Studies on EGFR signaling in both
vertebrates and invertebrates have
converged on several evolutionarily
conserved signaling cassettes that are
required to transmit the signal from
the receptor to the nucleus or to the
cytoplasm (Figure 2). The first
signaling cascade shown to be
downstream of the EGFR was the
Ras–mitogen-activated protein
kinase or MAP kinase pathway.
When the pathway is activated, the
SOS guanine nucleotide exchange
factor is recruited to the plasma
membrane via the Grb2/Drk/Sem5
adapter protein. SOS stimulates the
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Figure 2
Downstream of EGFR. EGFR activity is
transduced to the cell via a number of
conserved signaling cascades. For details
see text. Phosphorylated tyrosine residues of
the EGFR recruit various adapter proteins
with SH2 or PTB domains to the membrane:
Y992, docking site of PLCγ; Y1045, docking
site of Cbl; Y1068 and Y1086, docking sites
of Grb2—Drk in Drosophila, Sem5 in
C. elegans; Y1148 and Y1173, docking sites
of Shc, Shp1 and PLCγ.
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exchange of GTP for GDP on the
small G-protein Ras. Subsequently
activated Ras stimulates the MAP
kinase pathway to promote cell
proliferation.
In addition to the MAP kinase
pathway, PLCγ and
phosphatidylinositol 3-kinase — PI
3-kinase — are able to transduce
EGFR activity. PLCγ activates
second messenger systems which are
required for enhanced cell motility.
In this context PKC is activated and
phosphorylates T654 in the
juxtamembrane domain of the
EGFR. This leads to a preferential
disruption of the Ras–MAP kinase
pathway and further biases the
response to EGFR activation towards
cell motility. PI 3-kinase regulates a
number of downstream signaling
components. For example, the PI 3-
kinase-induced generation of H2O2
blocks the activity of the inhibitory
tyrosine protein phosphatase that
would otherwise terminate EGFR
activation. The complexity of
signaling is further increased by
cross-talk between individual
pathways. Ras is able to regulate PI
3-kinase activity, and PLCγ can
indirectly regulate Ras.
EGFR ligands
The number of ligands that can
activate the ErbB family has
increased during evolution. In
C. elegans there is a single ligand, in
Drosophila there are four and in
mammals more than a dozen ligands
have been identified. Generally, the
cysteine-rich domains of the EGFR
family members facilitate the
binding of a diverse family of
extracellular ligands such as TGF-α,
EGF or Neuregulins, all of which
contain a single EGF-like motif in
their extracellular domain.
Six ligands are known to activate
the EGFR: TGF-α, EGF,
Amphiregulin, heparin-binding
EGF-like growth factor, Betacellulin
and Epiregulin. However no ligand is
known for ErbB2. ErbB3 and ErbB4
bind to Neuregulins — a diverse
family of more than fifteen proteins,
all generated from a single gene.
ErbB3 has no kinase activity and
thus acts as a regulatory receptor. 
Binding of EGF to EGFR favors
dimerization of the receptor to form a
complex containing two molecules of
ligand and two molecules of receptor.
The EGFR can also form
heterodimers with ErbB2, which has
a reduced internalization capacity
compared with EGFR. This
decreases EGFR downregulation
and thus prolongs signaling from the
EGFR.
EGFR ligands include both
secreted molecules as well as
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Figure 3
Negative regulators of EGFR signaling.
Several proteins were found to attenuate
EGFR signaling. Argos, Decorin, and Kekkon
bind to the extracellular domain of the EGFR.
PKC is able to phosphorylate the EGFR at
T654. Binding of Cbl at Y1045 results in
ubiquitination and subsequent degradation.
The recently identified Echinoid protein
interferes with EGFR signaling downstream.
LRR, leucine-rich repeat; Ig, immunoglobulin-
like domain; FnIII, fibronectin type III repeat.
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membrane-tethered forms that have
a long, intracellular cytoplasmic
domain. It has been shown for TGF-
α, its Drosophila homologue Spitz
and the Neuregulins that proteolytic
processing is required to generate
the active ligand from the
transmembrane precursor. The
cytoplasmic protein domains control
proteolytic processing and may
themselves have signaling properties,
although this has not yet been
explored in detail.
In Drosophila three EGFR
agonists have been characterized —
Spitz, Vein and Gurken. A fourth
ligand called Keren has been
deduced from the Drosophila genome
sequence, though no mutants are
known. The spitz gene encodes a
TGF-α homologue. Proteolytic
cleavage of its membrane-bound
precursor by a still unknown protease
requires the genes rhomboid and Star.
The resulting highly potent agonist
of the Drosophila EGFR accounts for
most of the EGFR activity during
embryogenesis. The transmembrane
protein Vein resembles the
vertebrate Neuregulins and also
activates the Drosophila EGFR. The
Gurken protein is related to TGF-α
and plays a pivotal role during the
establishment of both the
anterior–posterior and the
dorsal–ventral axes of the Drosophila
oocyte. As well as binding to many
different ligands, the extracellular
domain of the Drosophila EGFR can
also interact with other membrane-
bound proteins such as Kekkon,
which are able to attenuate EGFR
signaling activity.
EGFR antagonists
Inhibitory signaling is an important
way of fine tuning EGFR activity to
enable a cell to discriminate between
short and prolonged exposure to
signaling molecules. Over the last
few years a number of different
mechanisms have been shown to
abrogate receptor activity (Figure 3).
First, inhibitory signaling molecules
are expressed in response to EGFR
activation. The most prominent
example is encoded by the
Drosophila gene argos. Argos is a
secreted molecule that has a single
EGF-like domain with an expanded
B-loop. Binding experiments showed
that Argos binds directly to the
EGFR presumably via its EGF-like
domain and inhibits EGFR activity.
Argos prevents Spitz binding and
may also interfere with ligand-
independent activation of the EGFR
by preventing the formation of active
EGFR dimers.
Besides Argos a number of other
molecules attenuate EGFR activity.
Again Drosophila has been a powerful
system for identifying new
components which can inhibit
EGFR. Kekkon, which is expressed
in response to EGFR activity,
encodes a type I transmembrane
protein and resembles cell adhesion
molecules. The extracellular domain
of Kekkon binds to the EGFR and
provides a mechanism for negative-
feedback . Two additional Kekkon-
like proteins are encoded by the
Drosophila genome which await
characterisation. 
The Echinoid protein shows
identity to the L1 adhesion protein
and defines an additional pathway
for antagonizing EGFR activity
downstream of the receptor. EGFR
activity can also be influenced by
components of the extracellular
matrix. One example is the leucine-
rich proteoglycan Decorin that can
bind EGFR and attenuate EGFR
phosphorylation.
sprouty and the cbl are genes
which encode global inhibitors of
EGFR signaling. Sprouty contains a
conserved cysteine-rich domain and
associates with components of the
EGFR signaling cascade such as
Grb2/Drk and GAP1. The function
of Sprouty is, however, not restricted
to the EGFR pathway. Cbl contains
an unusual SH2 domain that is
responsible for EGFR binding via
Y1045. This interaction leads to the
phosphorylation of Cbl, which may
facilitate the ubiquitin ligase activity
of the Cbl RING finger domain.
Ubiquitination of the EGFR leads to
its internalization via clathrin-coated
vesicles and subsequent degradation.
In summary, EGFR signaling
appears to be integrated in a complex
regulatory network linking
extracellular signals to the cytoplasm
and the nucleus. In the last decade
the modulation of EGFR activity by
negative regulators has become more
and more evident. Now the picture is
getting even more complicated by
the fact that differential trafficking of
activated EGFR may lead to
different cellular responses. Further
studies may not only help to increase
our understanding of the role of
EGFR signaling in the developing
animal, they may ultimately lead to
the development of efficient anti-
cancer therapeutics.
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